BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

周一，Jefferies重申了对BioNTech SE（NASDAQ:BNTX）的股票评级和目标价，维持买入评级，目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示，公司收入约为11.9亿欧元，略高于市场预期的11.8亿欧元。得益于运营支出的降低，每股收益（EPS）达到1.08欧元，同样超过了市场预期的0.77欧元。根据 InvestingPro ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

这家德国生物科技公司第四季度每股收益达到€1.08，超过分析师预期。营收为€11.9亿，高于€11.2亿的市场预期。 2024财年，BioNTech录得净亏损€6.653亿，即每股亏损€2.77，而2023年同期为净利润€9.303亿，每股收益€3.83。全年营收从上年的€38.2亿下降至€27.5亿。

Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

US stocks looked set to build on losses of over 2% for the major indexes as March's struggles looked to continue.

AstraZeneca and Ionis’ Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary ...